APPLICATION
Application Note
IP: Use at a concentration of 1 - 2 μg/ml. WB: Use at a concentration of 1 - 5 μg/ml. Predicted molecular weight: 145 kDa. Optimal dilutions/concentrations should be determined by the end user.
Calculated MW
Positive Control
K562 (human bcr/abl protein), ANN-1 (mouse abl protein), HL-60 (human normal abl protein), or NIH 3T3 (mouse normal abl protein) cells
Product Note
Reacts with both c- and v-abl encoded proteins and inhibits abl protein tyrosine kinase activity. The antibody recognizes v-abl, CML c-bcr/abl p210, human ALL c-bcr/abl p190, human c-abl p145, and mouse c-abl p150 proteins.
PROPERTIES
Form
Liquid
Buffer
50mM Sodium Phosphate, 0.2% Gelatin
Preservative
0.1% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
TrpE-abl fusion protein pEX-2.
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
ABL proto-oncogene 1, non-receptor tyrosine kinase , ABL , CHDSKM , JTK7 , bcr/abl , c-ABL , c-ABL1 , p150 , v-abl
Cellular Localization
Cytoplasm, cytoskeleton , Nucleus , Mitochondrion
Background
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]
Database
Research Area
REFERENCE
There are currently no references for c-Abl antibody [19-110] (GTX16903). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for c-Abl antibody [19-110] (GTX16903). Be the first to share your experience with this product.
